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BACKGROUND: 16p11.2 breakpoint 4 to 5 copy number variants (CNVs) increase the risk for developing autism
spectrum disorder, schizophrenia, and language and cognitive impairment. In this multisite study, we aimed to
quantify the effect of 16p11.2 CNVs on brain structure.
METHODS: Using voxel- and surface-based brain morphometric methods, we analyzed structural magnetic
resonance imaging collected at seven sites from 78 individuals with a deletion, 71 individuals with a duplication,
and 212 individuals without a CNV.
RESULTS: Beyond the 16p11.2-related mirror effect on global brain morphometry, we observe regional mirror
differences in the insula (deletion . control . duplication). Other regions are preferentially affected by either the
deletion or the duplication: the calcarine cortex and transverse temporal gyrus (deletion . control; Cohen’s
d . 1), the superior and middle temporal gyri (deletion , control; Cohen’s d , 21), and the caudate and
hippocampus (control . duplication; 20.5 . Cohen’s d . 21). Measures of cognition, language, and social
responsiveness and the presence of psychiatric diagnoses do not influence these results.
CONCLUSIONS: The global and regional effects on brain morphometry due to 16p11.2 CNVs generalize across site,
computational method, age, and sex. Effect sizes on neuroimaging and cognitive traits are comparable. Findings
partially overlap with results of meta-analyses performed across psychiatric disorders. However, the lack of
correlation between morphometric and clinical measures suggests that CNV-associated brain changes contribute
to clinical manifestations but require additional factors for the development of the disorder. These findings
highlight the power of genetic risk factors as a complement to studying groups defined by behavioral criteria.
Keywords: 16p11.2, Autism spectrum disorder, Copy number variant, Genetics, Imaging, Neurodevelopmental
disorders
https://doi.org/10.1016/j.biopsych.2018.02.1176Autism spectrum disorder (ASD) and related neurodevelopmental
disorders are defined behaviorally and characterized by a signif-
icant clinical and etiologic heterogeneity. As a consequence,
investigating ASD under the assumption of an underlying homo-
geneous condition has resulted in controversial findings in the
field of neuroimaging (1). Increased brain growth early in devel-
opment (2–4) and alterations of many regional brain volumes (5)
have been implicated in ASD, but results have proven difficult
to replicate (1,6–8).
To mitigate some of these issues, cohorts of individuals with
shared genetic risk factors have been assembled to minimize the
noise introduced by etiologic and biological heterogeneity (9).
Such a “genetic-first” study design provides the opportunity toSEE COMMENTARY
ª 2018 Society of B
CC BY-NC-ND
N: 0006-3223 Bioloinvestigate a given neurodevelopmental risk (and associated
mechanism) shared by individuals who carry the same genetic
etiology irrespective of the psychiatric diagnosis.
Copy number variants (CNVs) at the 16p11.2 (breakpoints
4–5, 29.6–30.2 Mb-hg19) (10) are among the most frequent risk
factors for neurodevelopmental and psychiatric conditions.
There is a similar 10-fold enrichment of deletions and dupli-
cations in ASD cohorts (11,12), and both CNVs have large
effects on IQ (Z scores of 1.5 and 0.8, respectively) and Social
Responsiveness Scale (SRS) (Z scores of 1 and 2, respectively)
(10,13–15). However, there are phenotypic differences be-
tween both CNVs: the 10-fold enrichment in schizophrenia
cohorts (16,17) is only observed for duplications, and onlyON PAGE 234
iological Psychiatry. This is an open access article under the
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Psychiatrydeletions affect measures of language by 1.5 Z scores (18).
Previous studies demonstrated “mirror” effects of both CNVs
on head circumference and body mass index (13,19). Neuro-
imaging studies reported gene-dosage effects on global brain
metrics (20,21). However, large global effects and sample size
limited the interpretation of the regional analyses, any estimate
of effect size, and the generalizability of study results across
different ascertainments.
In the current study, we aimed at quantifying the effects of
16p11.2 deletions and duplications on brain structure. We also
examined the generalizability of our results across cohorts,
scanning sites, sex, and a broad age range. Finally, we aimed
at understanding the influence of clinical ascertainment. In
particular, we asked whether language, social responsiveness,
IQ, or the presence of psychiatric disorders may impact any of
the findings. To this end, we analyzed structural magnetic
resonance imaging (MRI) performed at seven sites from two
international cohorts of 16p11.2 CNV carriers, familial control
subjects, and unrelated control subjects. Voxel- and surface-
based methods were performed in parallel on 361 partici-
pants, including 307 individuals not previously analyzed at the
regional level, using whole-brain statistical methods.
METHODS AND MATERIALS
Participants
Data were acquired in two different cohorts in North America
and Europe. Enrollment in the Simons Variation in Individuals
Project (22) included referral by clinical genetic centers or web-
based networks, or active online registration of families, while
in the European 16p11.2 consortium the families were directly
recruited by the referring physician.
Carriers were ascertained regardless of clinical diagnoses or
age. The CNV carriers were either probands (n = 76) referred to
the genetic clinic for the investigation of neurodevelopmental
and psychiatric disorders, or their relatives (parents [n = 49],
siblings [n = 14], and other relatives [n = 10]). Familial control
subjects were relatives who do not carry a 16p11.2 CNV.
All families participated in a larger phenotyping project, as
previously reported (10,13,20–22). Trained neuropsychologists
performed all cognitive and behavioral assessments, including
tests of overall cognitive functioning (nonverbal IQ [NVIQ])
(23–27) and phonological skills (standard score of the nonword
repetition) (28,29). Participants also completed a broad
screening measure of social impairment, the SRS (30). Expe-
rienced, licensed clinicians provided clinical DSM-5 diagnoses
(31), using all information obtained during the research evalu-
ation. NVIQ scores and psychiatric diagnoses were available
for all participants. SRS total score was available for 77% of
the participants (72 of 78 deletion carriers, 57 of 71 duplication
carriers, and 149 of 212 control subjects), and phonological
measures for 43% of the participants (56 of 78 deletion car-
riers, 19 of 71 duplication carriers, and 81 of 212 control
subjects). Full description of cognitive and psychiatric
assessment is available in the Supplemental Methods and
Materials.
We analyzed data from 78 16p11.2 (breakpoints 4–5) dele-
tion carriers, 71 duplication carriers, 72 familial control sub-
jects, and 140 unrelated control subjects, including data not
previously analyzed at the regional level on 64 deletion carriers,254 Biological Psychiatry August 15, 2018; 84:253–264 www.sobp.org54 duplication carriers, 51 familial control subjects, and 138
unrelated control subjects. The latter were selected among
volunteers from the general population who had neither a
major DSM-5 diagnosis nor a relative with a neuro-
developmental disorder.
The study was approved by the institutional review boards
of each consortium. Signed informed consent was obtained
from the participants or legal representatives. Full description
of participants is available in Table 1, Supplemental Table S1,
and the Supplemental Methods and Materials.
MRI Data Acquisition and Processing
The MRI data included T1-weighted (T1w) anatomical images
acquired at seven sites using different 3T whole-body scan-
ners: Philips Achieva (Philips Healthcare, Andover, MA) and
Siemens Prisma Syngo and TIM Trio (Siemens Corp., Erlangen,
Germany). Four sites used multiecho sequences for 264 par-
ticipants (52 deletion carriers, 51 duplication carriers, 21 fa-
milial control subjects, and 140 unrelated control subjects),
and three sites used single-echo sequences for 97 participants
(26 deletion carriers, 20 duplication carriers, and 51 familial
control subjects). Thirty-four scans were excluded from the
analysis based on standardized visual inspection, which
identified significant artifacts potentially compromising the
accurate tissue classification and boundary detection (details
in Supplemental Methods and Materials).
Surface-Based Morphometry. In FreeSurfer 4.5.0 (http://
surfer.nmr.mgh.harvard.edu), each participant’s T1w image
was registered to a custom hybrid template consisting of 48
subjects (12 deletion children, 12 noncarrier children, 12 dupli-
cation adults, and 12 noncarrier adults) (21). Then, we used
FreeSurfer’s volumetric (32) and surface-based (33) algorithms
with default settings. We estimated the total intracranial volume
(eTIV) (34), global brain measures, cortical thickness, and sur-
face area. The cortical thickness and surface area maps were
resampled in fsaverage5 space and spatially smoothed with a
Gaussian kernel of 8-mm full width at half maximum.
Voxel-Based Morphometry. In parallel we processed
subjects’ T1w data within the computational anatomy frame-
work of SPM12 (http://www.fil.ion.ac.uk/spm). T1w images
were classified in different brain tissue classes using the
“unified segmentation” (35) and an enhanced set of brain tis-
sue priors (36). Aiming at optimal spatial registration, we
applied the diffeomorphic registration algorithm DARTEL (37)
followed by a Gaussian spatial smoothing with 8-mm full
width at half maximum. Of note, total intracranial volume
computed by SPM is referred to as TIV.
Regions of interest were extracted using maximum proba-
bility tissue labels (http://www.neuromorphometrics.com)
within SPM12 using data from the OASIS project (http://www.
oasis-brains.org).
All MRI scanning parameters and processing are detailed in
the Supplemental Methods and Materials.
Data Analysis
Our whole-brain voxel-based morphometry (VBM) (38) analysis
used a factorial design to test for gene dosage–related local/journal
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Psychiatrygray matter (GM) volume differences within the general linear
model framework of SPM12 (39). SPM t maps were generated
with a voxel-level threshold of p , .05 after familywise error
correction for multiple comparisons over the whole GM volume
using Gaussian random field theory (40). We generated
Cohen’s d maps from familywise error–corrected t scores to
show the unbiased magnitude of the effects (Supplemental
Methods and Materials).
Surface-based analyses tested regional differences in
cortical thickness and surface area using linear models. For
each vertex in the cerebral cortex surface mesh, we ran a
multiple regression analysis. The vertexwise results were cor-
rected for multiple comparisons at a false discovery rate of q ,
.05 (41,42) (Supplemental Methods and Materials).
The main effects of linear and quadratic expansions of age,
sex, MRI site, and NVIQ were included as additional variables.
The cubic expansion of age did not show any significant effect
and was subsequently removed from all analyses. In an
attempt to increase the power of our analyses we controlled for
the effect of the seven scanning sites by introducing them as a
random factor in a linear mixed model. This approach did not
change the obtained results.
Z scores for global brain metrics were obtained in CNV car-
riers and familial control subjects using the adjusted measures
from unrelated control subjects as the reference population.
Regional analyses were also corrected for the SPM estimate
of TIV, the mean cortical thickness, or the total cortical surface
area. In addition to the linear effect of gene dosage, we
investigated the quadratic term to identify nonreciprocal ef-
fects of both CNVs. Post hoc analyses comparing deletion
carriers and control subjects as well as duplication carriers and
control subjects identified regions predominantly altered by
each CNV.
We analyzed the interaction of the genetic groups with the
regressors (age, sex, MRI site, NVIQ) as well as the MRI pa-
rameters (single-echo vs. multiecho) and three other clinical
variables: SRS, phonological processing (nonword repetition),
and psychiatric diagnoses. NVIQ did not show any significant
effect and was removed from the analyses on the whole
dataset. Dice index was computed to estimate the overlap
between 16p11.2-related alterations and statistical maps ob-
tained from a large cross-disorder neuroimaging meta-analysis
(http://anima.fz-juelich.de) (43). We computed the rate of
overlap between both maps. Finally, to motivate future hy-
potheses we relied on the Neurosynth database (http://
neurosynth.org) to meta-analytically decode the functional
association of the structural alterations observed in the gene
dosage analyses of the 16p11.2 CNV carriers. All these ana-
lyses are detailed in the Supplemental Methods and Materials.
Linear models on global metrics and regions of interest were
performed in R, version 3.2.5 (http://www.r-project.org; R
Project for Statistical Computing, Vienna, Austria), and voxel-
and surface-based analyses in MATLAB 2016b (The Math-
Works, Inc., Natick, MA).
RESULTS
Demographics
We analyzed 78 deletion carriers, 71 duplication carriers, and
212 familial and unrelated control subjects (Table 1,ychiatry August 15, 2018; 84:253–264 www.sobp.org/journal 255
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PsychiatrySupplemental Table S1), including new data on 138 individuals
and data on 307 individuals not previously analyzed with
whole-brain statistical methods. Age ranges from 6 to 63
years. Deletion carriers and control subjects from the Simons
Variation in Individuals Project cohort are younger than the
same groups in the European cohort, and deletion carriers
overall are younger than the other groups. There is no sig-
nificant difference in sex ratio across genetic groups and
cohorts. Mean NVIQ is 81 and 89 in deletion carriers, and 78
and 89 in duplication carriers for the European and Simons
Variation in Individuals Project cohorts, respectively. Ninety
percent of the deletion carriers, 69% of the duplication
carriers, and 25% of familial control subjects meet criteria for
at least one psychiatric diagnosis. Twelve categories of di-
agnoses are recorded across the CNV carrier groups,
including ASD in 13% of deletion carriers and 11% of
duplication carriers (Table 2).
Global Brain Metrics
Head circumference Z scores (Table 1) and eTIV (Figure 1A)
correlate negatively with the number of genomic copies of the
16p11.2 locus in both cohorts. Both GM and white matter total
volumes contribute to this effect on eTIV (Figure 1B, C). The
effect sizes on global brain metrics are up to 1 Z score for the
deletion and approximately 20.4 Z score for the duplication
(Supplemental Table S2). FreeSurfer and SPM estimates ofTable 2. DSM-5 Diagnoses
Deletio
EU (n = 25) SV
Neurodevelopmental Disorders 3
Intellectual Disability
Communication disorder 16
Autism spectrum disorder –
Attention-deficit/hyperactivity disorder 2
Specific learning disorder 1
Motor disorder, tic disorder –
Schizophrenia Spectrum and Other Psychotic Disorders –
Bipolar and Related Disorders –
Depressive Disorders 2
Anxiety Disorders 2
Obsessive-Compulsive and Related Disorders 1
Trauma and Stressor-Related Disorders 1
Elimination Disorders 5
Disruptive, Impulse-Control, and Conduct Disorders 1
Substance-Related and Addictive Disorders 3
Feeding and Eating Disorders –
Other Conditions That May Be a Focus of Clinical Attention –
From the DSM-5 (31).
A total of 20 of 25 European (EU) cohort deletion carriers (80%) had at le
diagnoses (between two and five); 17 of 23 EU cohort duplication carriers (7
had several diagnoses (two or three); 9 of 45 familial control subjects (20%)
two diagnoses. In the Simons Variation in Individuals Project (SVIP) dataset,
6 had one diagnosis and 44 had several diagnoses (between two and eight)
diagnosis: 10 had one diagnosis and 22 had several diagnoses (between
psychiatric diagnosis: 4 had one diagnosis and 5 had two diagnoses. In b
were recruited.
256 Biological Psychiatry August 15, 2018; 84:253–264 www.sobp.orgTIV, GM, and white matter are comparable across groups,
cohorts, and MRI parameters (Supplemental Figure S1). Gene
dosage preferentially affects cortical surface area and not
thickness (Figure 1E, F). Of note, age-related thinning of
cortical thickness is not significantly different between genetic
groups (Supplemental Figure S2).
Regional Brain Differences Related to the 16p11.2
CNVs
In both cohorts, the whole-brain VBM analysis shows a
negative relationship between the number of genomic
copies at the 16p11.2 locus and the volume of several brain
regions. Alterations with an effect size .1 Cohen’s
d (detected with a conservative power of 74.4% for family-
wise error–corrected p , .05) include the bilateral anterior
and posterior insula, transverse temporal gyrus, and cal-
carine cortex (Figure 2A, Supplemental Table S3). Regions
with smaller volumes in deletion carriers compared with
control subjects and duplication carriers include the bilateral
precentral gyrus and middle and superior temporal gyri.
Altered regions with smaller effect sizes are detailed in
Supplemental Table S3.
There is a high degree of overlap between VBM findings
with large effects and regional cortical surface area alterations,
namely the insula, transverse temporal gyrus, and calcarine
cortex (negative gene dosage), as well as the precentral gyrusn Familial Control Subjects Duplication
IP (n = 53) EU (n = 45) SVIP (n = 27) EU (n = 23) SVIP (n = 48)
5 – – 4 6
53 – 2 – 3
10 – 1 2 6
12 2 4 1 7
14 1 – 4 4
26 – 1 1 9
– – – 1 –
– – – 1 –
3 7 1 5 9
7 – 3 9 13
1 – – 1 2
– – – – 2
14 – 2 1 2
5 – – – –
– – – 1 –
– 2 – – –
9 – – – 9
ast one psychiatric diagnosis: 11 had one diagnosis and 9 had several
4%) had at least one psychiatric diagnosis: 7 had one diagnosis and 10
had at least one psychiatric diagnosis: 6 had one diagnosis and 3 had
50 of 53 deletion carriers (94.3%) had at least one psychiatric diagnosis:
; 32 of 48 SVIP duplication carriers (66.6%) had at least one psychiatric
two and five); 9 of 27 familial control subjects (33%) had at least one
oth cohorts, unrelated control subjects without psychiatric diagnosis
/journal
Figure 1. Effects of gene dosage on global brain measures in the European (EU) and Simons Variation in Individuals Project (SVIP) cohorts. Boxplots of (A)
estimated total intracranial volume (eTIV), (B) gray matter (GM) volume, (C) white matter (WM) volume, (D) ventricular volume, (E) cortical surface area, and (F)
mean cortical thickness in each genetic group separately for the EU and SVIP cohorts. Gene dosage effect is estimated with a linear model using the number of
16p11.2 genomic copies (1, 2, or 3), and including linear and quadratic expansions of age, sex, nonverbal IQ, and magnetic resonance imaging site as fixed
covariates. In each box, the bold line corresponds to the median. The bottom and top of the box show the 25th (quartile 1 [Q1]) and 75th (quartile 3 [Q3])
percentiles, respectively. The upper whisker ends at the largest observed data value within the span from Q3 to Q3 1 1.5 3 the interquartile range (Q3 2 Q1),
and lower whisker ends at the smallest observed data value within the span for Q1 to Q12 (1.53 interquartile range). Circles that exceed whiskers are outliers.
Post hoc comparisons show Bonferroni-corrected p values.
Effects of 16p11.2 Copy Number Variants on Neuroanatomy
Biological
Psychiatryand superior and middle temporal gyri (positive gene dosage).
Regions with smaller effect size and no overlap are shown in
Figure 3; Supplemental Figure S3A, C; and SupplementalBiological PsTable S4. Cortical thickness, on the other hand, shows little
overlap with the VBM results (Figure 3; Supplemental
Figure S3B, D; and Supplemental Table S5).ychiatry August 15, 2018; 84:253–264 www.sobp.org/journal 257
Figure 2. Effects of gene dosage on regional gray matter volume in the Europe (EU) and Simons Variation in Individuals Project (SVIP) cohorts. (A) Left
panels (deletion . duplication) show voxel-based whole-brain maps, with the volumes of regions showing a negative relationship with the number of 16p11.2
genomic copies. Right panels (deletion , duplication) present the volumes of regions showing a positive relationship with the number of 16p11.2 genomic
copies. (B) Negative and positive gene dosage effects on gray matter volume following a leave-one-out approach by systematically removing one of the
magnetic resonance imaging sites. All the analyses are controlled for linear and quadratic expansions of age, sex, magnetic resonance imaging site, total
intracranial volume, and nonverbal IQ. Results significant at a threshold of p , .05 familywise error corrected for multiple comparisons are displayed in
standard Montreal Neurological Institute space. Color bars represent Cohen’s d. L, left; R, right.
Effects of 16p11.2 Copy Number Variants on Neuroanatomy
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PsychiatryThese regional results are not influenced by subjects’ age,
sex, cohort, MRI site, or MRI protocol (multiecho vs. single-
echo): None of the variables shows an interaction with genetic
groups (Figure 2B, Supplemental Figures S4 and S5A). In
particular, a subgroup of participants who underwent both
multi- and single-echo protocols presents the same alterations
(Supplemental Figure S5B). NVIQ does not show any main
effect on regional brain structure and was removed as a co-
variate for the subsequent analyses. Given the above obser-
vations, we pooled all data.
Relationship Between Total Brain Volume and
Regional Differences
We examined the contribution of global differences to regional
alterations. There was no relationship between global metrics
and any of the aforementioned large effect regional findings,258 Biological Psychiatry August 15, 2018; 84:253–264 www.sobp.orgeven after adding GM volume as a covariate in the VBM ana-
lyses. We then tested for correlations between eTIV and the
raw or adjusted volumes of some significant regions
(Supplemental Figure S6). This demonstrates that small,
average, or large brains contribute equally to the regional ef-
fects of 16p11.2 CNVs.
Mirror Effects Versus Differential Contribution of
CNVs to Regional Differences
To differentiate reciprocal from nonreciprocal effects driven by
either the deletion or the duplication carriers, we compared the
linear and quadratic effects of gene dosage. The nonreciprocal
effects of the 16p11.2 deletion and duplication identified by the
quadratic term are detailed in Supplemental Figure S7. Post
hoc analyses show that the deletion preferentially impacts the
volume and surface area of the calcarine cortex and the/journal
L Lateral
L Medial
R Lateral
R Medial
L Lateral
L Medial
R Lateral
R Medial
VBM Only
Surface Area Only
A B
Figure 3. Overlap between voxel-based and surface-based results for cortical alterations associated with gene dosage. The relationship between gene
dosage and the morphometric features was compared in the pooled sample (n = 361). The voxel-based and surface-based statistical maps are thresholded at
the multiple comparisons–corrected p value and then projected on the cortical surface mesh. Regions with effect size $1 Cohen’s d and overlapping between
voxel-based and surface-based analyses are (A) the bilateral insula, transverse temporal gyrus, calcarine cortex and (B) the precentral, superior and middle
temporal gyri. L, left; R, right; VBM, voxel-based morphometry.
Effects of 16p11.2 Copy Number Variants on Neuroanatomy
Biological
Psychiatrytransverse temporal gyrus (deletion . control) and the superior
and middle temporal gyri (deletion , control), with absolute
effect size .j1j Cohen’s d. The duplication carriers do not
show any neuroanatomical differences with effect size .j1j
Cohen’s d. We observe GM volume changes in the caudateFigure 4. Differential and overlapping contribution of deletion and duplication
whole-brain maps from the conjunction analysis of both negative (deletion . co
trol , duplication) gene dosage. The main mirror pattern is the insula. (B) Resul
larger volume in deletion carriers compared with control subjects (deletion .
duplication), in regions with smaller volume in deletion carriers compared with c
duplication carriers (control , duplication). Results significant at a voxel-level th
displayed in standard Montreal Neurological Institute space. Color bars represent
DEL, deletion carriers; DUP, duplication carriers; L, left; R, right.
Biological Psand hippocampus with Cohen’s d between j0.5j and j1j
(duplication , control) (Figure 4B, Supplemental Table S6).
Differences with smaller effect sizes or identified only by one of
the analytical methods such as alterations in the cerebellum,
precentral gyrus, and cingulate are detailed in theto the regional gray matter volume differences. (A) Results of voxel-based
ntrol AND control . duplication) and positive (deletion , control AND con-
ts of voxel-based whole-brain maps showing the effect size in regions with
control), in control subjects compared with duplication carriers (control .
ontrol subjects (deletion , control), and in control subjects compared with
reshold of p , .05 familywise error corrected for multiple comparisons are
t scores for panel (A) and Cohen’s d for panel (B). CTRL, control individuals;
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S9C–F.
The reciprocal mirror effects of the 16p11.2 deletion and
duplication are restricted to the bilateral insula. The post hoc
conjunction analysis shows that the deletion is associated with
an increase of the volume and surface area of the insula, and
the duplication is associated with a decrease of this region
(Figure 4A, Supplemental Table S6). We do not observe
reciprocal effects of gene dosage for cortical thickness mea-
surements (Supplemental Figure S9A, B).Relationship With Psychiatric Diagnosis and
Cognitive Traits
Because the 16p11.2 locus is associated with more than one
psychiatric diagnosis, we quantified the overlap of our findings
with a large, cross-disorder neuroimaging meta-analysis
[http://anima.fz-juelich.de (43)]. We observe that the 16p11.2-
related VBM map overlaps 33% of the meta-analytic map
(Dice index): 46% for the cluster including the left insula, 28%
for the right insula, and none for the dorsal anterior cingulate
cortex.
We used Neurosynth to meta-analytically decode the psy-
chological terms most closely associated with the main
anatomical clusters identified in the VBM analysis. Supplemental
Table S7 illustrates the domains most associated with each
cluster. The transverse, superior, and middle temporal gyri (re-
gions predominantly affected in deletion carriers) show top as-
sociations with language, phonology, and auditory terms. The
anterior insula and caudate (alterations found in duplication
carriers) are associated with terms such as reward, pain, and
executive function (Supplemental Figure S10). Recognizing such
inverse inferences can provide hypotheses for future studies but
are unable to support strong conclusions.Figure 5. Contribution of familial control subjects to the regional gene dosage
brain maps showing (A) regions with larger volume in control subjects from delet
(B) regions with smaller volume in control subjects from duplication families (n = 2
voxel-level threshold of p, .05 familywise error corrected for multiple comparison
represent effect size (Cohen’s d). L, left; R, right.
260 Biological Psychiatry August 15, 2018; 84:253–264 www.sobp.orgHowever, the measures of NVIQ, SRS, and phonological
processing measured in participants do not show main effects
or interact with the gene dosage effects. The presence of low
general intelligence (NVIQ), language impairment (measured by
phonological processing), or poor social skills (SRS), or the
presence and number of comorbid psychiatric diagnoses,
does not change any of the neuroanatomical findings associ-
ated with the 16p11.2 deletion or duplication.
Ascertainment and Additional Factors Contributing
to Changes in Brain Structure
We tested whether ascertaining carriers for neuro-
developmental symptoms could bias our results. Because
clinical ascertainment may enrich as well for additional neu-
rodevelopmental factors present in CNV carriers and their
families, we investigated potential brain alterations in the family
members who do not carry a 16p11.2 CNV. Comparing control
subjects from deletion families (n = 51) and unrelated control
subjects shows changes in volume and thickness with medium
effect size (.0.5 Cohen’s d) of the left posterior insula and right
lingual gyrus; changes of volume also include the putamen and
hippocampus (Figure 5, Supplemental Figure S14E). No effect
was found for the cortical surface area (Supplemental
Figure S13E).
However, comparing deletion or duplication carriers with fa-
milial or unrelated control subjects does not change any of the
global (Supplemental Table S2 and Supplemental Figure S11) or
regional findings reported above (Supplemental Figures S12,
S13A–D, and S14A–D).
DISCUSSION
This large, multisite dataset combines new and previously
published data to expand our understanding of the neuroan-
atomical differences associated with 16p11.2 deletions and-dependent gray matter volume differences. Results of voxel-based whole-
ion families (n = 51) compared with unrelated control subjects (n = 140); and
1) compared with unrelated control subjects (n = 140). Results significant at a
s are displayed in standard Montreal Neurological Institute space. Color bars
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structure is generalizable across heterogeneously ascertained
cohorts and remains significant beyond differences in MRI
scanners, imaging protocols, analysis with two complementary
computational methods, sex, age, and presence and number
of comorbid psychiatric diagnoses. We extend previous neu-
roimaging studies by characterizing the reciprocal and differ-
ential effect of deletions and duplications on brain structure.
While 16p11.2 deletions and duplications impact reciprocally
bilateral insula [a gateway for sensory interoception, self-
recognition, and emotional awareness (44)], differences in
other brain areas are predominantly associated with either
CNV.
Recent publications have questioned the reliability of neu-
roimaging studies that are prone to both type I and II errors
(45). Our results provide robust estimates for CNV effect sizes
on brain structure. Our sample size is adequate to detect the
large effects associated with both CNVs, greatly reducing the
probability of spurious findings. In imaging genetics, it has
often been assumed that genetic variants may have larger
effects on imaging phenotypes than on clinical traits or psy-
chiatric risk (45). Our study shows, however, that the effect size
of CNVs on brain structure is similar to their effect previously
published for cognitive and behavioral traits (13,18). The effect
of the deletion is approximately twice that of the duplication for
global and regional brain volumes as well as clinical traits (such
as IQ loss) (13).
The brain regions showing gene dosage effects are
implicated in phonology, language, reward, and executive
function networks. These are diverse functions that are each
complex and heterogeneous. Nonetheless, the associations
raise hypotheses for future studies. Similarly, the spatial
overlap between our findings and the meta-analytical results
performed across all Axis I psychiatric diagnoses from the
DSM-IV-TR (43) may provide clues to pathological patterns
underlying the risk for psychiatric diagnoses conferred by
16p11.2 CNVs.
The effects of CNVs on brain structure are not changed by
ascertainment for either neurodevelopmental or psychiatric
symptoms. Differences in IQ, language ability, or social
responsiveness or the presence and number of psychiatric
diagnoses do not influence any of the findings. We have pre-
viously reported a similar observation for cognition showing
that the 16p11.2 deletion is associated with a decrease in IQ of
25 points regardless of whether carriers have intellectual dis-
abilities or intelligence in the normal range (13).
This observation is consistent with an additive model un-
derlying psychiatric disorders (46). Under this assumption,
brain alterations associated with CNVs contribute to, but do
not necessarily correlate with, a psychiatric diagnosis because
additional brain alterations or other factors are required for the
onset of the disorder. This is in agreement with studies
demonstrating that GM changes in the superior temporal gy-
rus, insula, and cingulate are observed in individuals both
diagnosed with psychosis and at high risk for developing
psychosis (47).
Contrasting familial and unrelated control subjects reveals
regional differences partially overlapping with the 16p11.2
gene dosage alterations. Of note, these alterations involve
cortical thickness as opposed to CNV-related cortical surfaceBiological Pschanges. This may suggest the presence of additional factors
in these families ascertained in the neurodevelopmental
clinic. Assortative mating in families (in particular when the
CNV is inherited) may also contribute to an increase of risk
factors (48).
We are not implying that our findings are specific to the
16p11.2 locus. Differences in global and local GM volumes
as well as surface and thickness have been observed in
similar regions in 22q11.2 deletion carriers, another large-
effect-size genetic risk factor for psychiatric conditions
(49–51). They are also reminiscent of decreased regional
volumes in brain areas associated with emotion and face
processing demonstrated in individuals with a 7q11.23
deletion (52,53). It is still unclear whether these shared al-
terations in brain structure relate to similar changes in tis-
sue properties and underlying molecular mechanisms, but
they may suggest neuroanatomical convergence across
different genetic risk factors. This is illustrated by a study of
several genetically modified mouse models of ASD and in-
tellectual disability showing that their regional neuroana-
tomical alterations can be grouped in three different
clusters (6).Limitations
The broad age range of our dataset (6–63 years of age) is a
potential limitation. However, we did not find any interaction
between age and effects of gene dosage. The global and
regional alterations remain unchanged in age-specific sub-
groups, with the caveat of a significant decrease in power
(Supplemental Figures S2 and S4A). The developmental
onset of global and regional differences in 16p11.2 CNV
carriers remains unknown, but the insula, striatum, and thal-
amus are also altered in a 7-day-old 16p11.2 deletion mouse
model (54,55), suggesting an early developmental effect.
However, specific anatomical effects are difficult to interpret
between humans and mouse models. The multisite data
represents another limitation and can introduce false-positive
findings. However, investigating the impact of sites using
main as well as random effects did not identify any biases
introduced by the different scanners: this means that the
effect of the CNV may be more important than the noise
introduced by the multiple MRI sites. Finally, the missing
clinical data may limit our power to detect correlations be-
tween the brain morphometric measurements and the
cognitive and clinical data.
The strong results of this multisite genetic-first neuro-
imaging study provide a robust characterization of 16p11.2
deletion and duplication effects on neuroanatomy. The
deletion and duplication of the same genetic interval may
affect brain regions in opposing ways, but other structures
are preferentially altered by one of the two CNVs. The
morphometric effect sizes are comparable to those previ-
ously recorded on cognitive traits. Results are generalizable
across sites, computational methods, age, sex, and ascer-
tainment for psychiatric or neurodevelopmental disorders.
This suggests that these brain alterations are related to the
risk conferred by the CNVs rather than the clinical manifes-
tations observed in carriers. This highlights the relevance of
studying genetic risk factors as a complement to groupsychiatry August 15, 2018; 84:253–264 www.sobp.org/journal 261
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Psychiatrydefined on the basis of behavioral criteria. Future longitudinal
studies are required to establish the onset of these
alterations.
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